$3.5 B

ALLO Mkt cap, 18-Jun-2021

$38.3 M

Allogene Therapeutics Revenue Q1, 2021
Allogene Therapeutics Net income (Q1, 2021)-33 M
Allogene Therapeutics EBIT (Q1, 2021)-33.2 M
Allogene Therapeutics Cash, 31-Mar-2021236.9 M
Allogene Therapeutics EV3.3 B

Allogene Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

R&D expense

151.9m144.5m193.0m

General and administrative expense

2.0k41.0m57.5m65.3m

Operating expense total

2.0k192.8m202.0m258.2m

EBIT

(2.0k)(192.8m)(202.0m)(258.2m)

Interest expense

3.4m

Pre tax profit

(2.0k)(211.6m)(184.9m)(250.2m)

Income tax expense

(117.0k)(331.0k)

Net Income

(2.0k)(211.5m)(183.8m)(250.2m)

EPS

(7.3)(1.8)

Allogene Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

92.4m175.1m183.4m

Prepaid Expenses

17.2m

Current Assets

468.0m544.6m845.1m

PP&E

8.6m56.4m118.8m

Total Assets

773.9m717.8m1.2b

Accounts Payable

12.3m9.3m10.4m

Current Liabilities

2.0k29.5m33.1m94.3m

Long-term debt

34.5m51.3m50.8m

Total Debt

34.5m51.3m50.8m

Total Liabilities

2.0k70.7m88.8m148.2m

Common Stock

5.0k121.0k124.0k140.0k

Preferred Stock

Additional Paid-in Capital

914.3m1.0b1.7b

Retained Earnings

(2.0k)(211.5m)(396.1m)(646.3m)

Total Equity

(2.0k)703.2m629.0m1.1b

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

1.1 x1.1 x1.1 x

Allogene Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.0k)(211.5m)(184.6m)(250.2m)

Depreciation and Amortization

1.5m5.0m7.6m

Accounts Payable

8.8m(985.0k)615.0k

Cash From Operating Activities

(44.7m)(137.3m)(115.1m)

Purchases of PP&E

(3.2m)(50.8m)(66.0m)

Cash From Investing Activities

(632.8m)164.1m(505.1m)

Cash From Financing Activities

771.2m59.0m633.6m

Net Change in Cash

93.7m85.7m13.4m

Income Taxes Paid

(117.0k)(331.0k)

Allogene Therapeutics Ratios

USDFY, 2017

Allogene Therapeutics Operating Metrics

Sep, 2018FY, 2018FY, 2019

Patients Included in Clinical Trials

182121

Pre-Clinical Phase Products

778

Phase I Trials Products

114

Office and Laboratory Space, square feet

89.54 k222.49 k200.94 k

Allogene Therapeutics Employee Rating

4.612 votes
Culture & Values
5
Work/Life Balance
4.5
Senior Management
4.5
Salary & Benefits
5
Career Opportunities
4
Source